Disagreement between capillary blood glucose and flash glucose monitoring sensor can lead to inadequate treatment adjustments during pregnancy.

Disagreement between capillary blood glucose and flash glucose monitoring sensor can lead to inadequate treatment adjustments during pregnancy. Diabetes Metab. 2019 Aug 12;: Authors: Sola-Gazagnes A, Faucher P, Jacqueminet S, Ciangura C, Laforgue DD, Pudar HM, Roussel R, Larger E Abstract OBJECTIVE: Continuous glucose monitoring tends to replace capillary blood glucose (CBG) self-monitoring. Our aim was to determine the agreement between CBG and a flash glucose monitoring system (Flash-GMS) in treatment decision-making during pregnancy. RESEARCH DESIGN AND METHODS: Insulin-treated women with either type 1 (n = 25), type 2 (n = 4) or gestational diabetes (n = 4) were included. A Flash-GMS sensor was applied for 14 days. Women scanned the sensor whenever they wished to monitor their CBG. The primary endpoint was the proportion of discordant therapeutic decisions they would have made based on Flash-GMS rather than CBG results. Glucose averages, mean absolute difference (MAD), mean absolute relative difference (MARD) and Flash-GMS accuracy were also estimated. RESULTS: Data for 40 14-day periods were available. Preprandial Flash-GMS and CBG values were 93 ± 42 mg/dL and 105 ± 45 mg/dL, respectively (P
Source: Diabetes and Metabolism - Category: Endocrinology Authors: Tags: Diabetes Metab Source Type: research

Related Links:

This letter outlines the recent updates to the Healthier You NHS Diabetes Prevention Programme and Type 1 diabetes glucose monitoring; including an update on Flash uptake and NHS Englands plans to provide continuous glucose monitoring (CGM) for pregnant women.
Source: NHS Networks - Category: UK Health Source Type: news
ConclusionsWomen in our study with pre-gestational diabetes were overweight, were older and had long-standing diabetes mellitus. Our patients with type 2 diabetes had a higher BMI, were older, had a shorter duration of diabetes mellitus and had better diabetes control compared to women with type 1 diabetes. Women treated with continuous subcutaneous insulin infusion had a higher rate of miscarriage with more congenital malformations. The initial inadequate diabetes control was significantly improved during pregnancy.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This 60-second advertisement for Trulicity, a medication for diabetes, is one of the most feel-good medication commercials I’ve ever seen. The narrator never uses the scare tactic of so many other ads, listing the terrible things that could happen if you don’t take the treatment. Instead, from start to finish, music, images, and spoken words deliver empowering, encouraging messages focused on helping your body to do what it’s supposed to be doing despite having diabetes. There’s a lot of good information here, but as in most direct-to-consumer health marketing there’s also some that’s mi...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Diabetes Drugs and Supplements Health Source Type: blogs
Conclusions/interpretationAll women with GDM should be intensively monitored for a decade, after which the risk for type 1 diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is recommended.
Source: Diabetologia - Category: Endocrinology Source Type: research
Basel, 1 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas ® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, CEO Roche Diagnostics. “Being able to reliably determi...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Abstract Hyperglycemia is the most common medical complication of pregnancy. It is a broad term that encompasses various forms of glucose dysregulation seen during pregnancy. The International Diabetes Federation estimates that 1 in 6 live births (16.8%) occur to women with some form of hyperglycemia; 16% of these due to overt diabetes in pregnancy (DIP) and the remaining 84% due to gestational diabetes mellitus (GDM). DIP maybe either preexisting diabetes (type 1 or type 2) antedating pregnancy, or overt diabetes first diagnosed during pregnancy. PMID: 32770722 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
This study aimed to determine the feasibility and effectiveness of Diabetes Group Prenatal Care to increase patient engagement in diabetes self-care activities. Study Design A pilot randomized controlled trial was conducted at two sites. Inclusion criteria were English or Spanish speaking, type 2 or gestational diabetes, 22 to 34 weeks of gestational age at first study visit, ability to attend group care at specified times, and willingness to be randomized. Exclusion criteria included type 1 diabetes, multiple gestation, major fetal anomaly, serious medical comorbidity, and serious psychiatric illness. Women were r...
Source: American Journal of Perinatology - Category: Perinatology & Neonatology Authors: Tags: Original Article Source Type: research
AbstractMaturity-onset diabetes of the young (MODY) is an unusual form of diabetes with specific features that distinguish it from type 1 and type 2 diabetes. There are 14 known subtypes of MODY, and mutations in three genes (HNF1A,HNF4A, GCK) account for about 95% of all MODY cases. Diagnosis usually occurs before the age of 25  years, although less frequent forms may occur more often—but not necessarily—later in life. The molecular diagnosis may tailor the choice of the most appropriate treatment, with the aim to optimize blood glucose control, reduce the risk of hypoglycemic events and long-term complic...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Conclusions/interpretationOur data on the efficacy of ART treatment in women with type 1 and type 2 diabetes is the first in this field. When compared with women without diabetes, women with type 1 diabetes had an equivalent chance of a live birth per embryo transfer whereas women with type 2 diabetes had a reduced chance. The findings in women with type 2 diabetes did not seem to be driven by obesity per se as the same pattern was seen in both normal-weight and obese women.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | PET Scan | Pregnancy | Science | Women